Publicaciones en colaboración con investigadores/as de Hospital Virgen de la Concha (32)

2020

  1. The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Metastatic tumors in the pancreas: The role of endoscopic ultrasound-guided fine-needle aspiration

    Revista Espanola de Enfermedades Digestivas, Vol. 111, Núm. 5, pp. 345-350

2018

  1. Limitation of life support techniques at admission to the intensive care unit: A multicenter prospective cohort study

    Journal of Intensive Care, Vol. 6, Núm. 1

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2015

  1. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

2014

  1. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?

    Blood, Vol. 124, Núm. 12, pp. 1887-1893

  2. Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels

    BMC Infectious Diseases, Vol. 14, Núm. 1

  3. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma

    Blood, Vol. 124, Núm. 8, pp. 1300-1303

  4. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

  2. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Blood, Vol. 119, Núm. 3, pp. 687-691

  3. Initial experience with EUS-guided cholangiopancreatography for biliary and pancreatic duct drainage: A Spanish national survey

    Gastrointestinal Endoscopy, Vol. 76, Núm. 6, pp. 1133-1141

  4. Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients

    BMJ Supportive and Palliative Care, Vol. 2, Núm. 4, pp. 328-333

  5. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

2011

  1. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

    Journal of Clinical Oncology, Vol. 29, Núm. 12, pp. 1627-1633

  2. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

    Leukemia, Vol. 25, Núm. 4, pp. 697-706

  3. Intensive care unit discharge to the ward with a tracheostomy cannula as a risk factor for mortality: A prospective, multicenter propensity analysis

    Critical Care Medicine, Vol. 39, Núm. 10, pp. 2240-2245

  4. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

    Blood, Vol. 118, Núm. 17, pp. 4547-4553

  5. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

    Blood, Vol. 117, Núm. 13, pp. 3613-3616

2010

  1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

    The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941